/* mobile /* end mobile MEDDESKTOP: 2010

Thursday, December 30, 2010

Medicare Part D Open Enrollment Ends Tomorrow (December 31, 2010)

The open enrollment season for Medicare Part D runs from November 15 through December 31. During this period newly eligible beneficiaries can choose a new drug plan and existing beneficiaries can review their current prescription drug plan to ensure that it best fits their needs.
To help beneficiaries navigate through the details of different drug plans, the Centers for Medicare and Medicaid recently updated its Plan Finder tool. Visit Medicare.gov to use the Plan Finder tool.

Wednesday, December 29, 2010

FDA Approves Impax Doryx(R) 75 And 100MG Generic Antibiotic Tablets

Impax Laboratories Inc announced that it had received the Food and Drug Administration's approval for the company's Generic Version of the Antibiotic drug, Doryx(R) in 75 and 100mg dosages.
The drug is used for treating rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax, including inhalational anthrax (post-exposure), alternative treatment for selected infections when penicillin is contraindicated, adjunctive therapy in acute intestinal amebiasis and severe acne, and prophylaxis of malaria.
There is an ongoing patent infringement lawsuit filed by Warner Chilcott Limited and Mayne Pharma International Pty. Ltd.on the Impax's generic version of the drug.
Following is the Press release by Impax

Impax Laboratories Receives Final FDA Approval for Generic Doryx(R) 75 and 100mg Tablets
HAYWARD, Calif., Dec 29, 2010 (BUSINESS WIRE) -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application for the generic version of Doryx(R) (doxycyline hyclate delayed-release) 75 and 100mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

In December 2008, Warner Chilcott Limited and Mayne Pharma International Pty. Ltd. filed suit against the Company in the U.S. District Court for the District of New Jersey, alleging patent infringement for the filing of the Company's ANDA. Litigation is ongoing.

Doryx(R) is a tetracycline-class antibacterial indicated for rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax, including inhalational anthrax (post-exposure), alternative treatment for selected infections when penicillin is contraindicated, adjunctive therapy in acute intestinal amebiasis and severe acne, and prophylaxis of malaria. According to Wolters Kluwer Health, U.S. sales of Doryx(R) 75 and 100 mg were approximately $25 million in the 12 months ended October 2010.

Tuesday, December 28, 2010

Tiotropium Bromide Aids In Treating Uncontrolled Asthma In Adults.

Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose asthma is poorly controlled by an inhaled glucocorticoid alone. Alternative treatments for adults with uncontrolled asthma are needed.

In a test involving a three-way, double-blind, triple-dummy crossover trial covering 210 patients with asthma, The team evaluated the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease but not asthma) to an inhaled glucocorticoid, as compared with a doubling of the dose of the inhaled glucocorticoid (primary superiority comparison) or the addition of the LABA salmeterol (secondary noninferiority comparison). 

The use of tiotropium resulted in a superior primary outcome, as compared with a doubling of the dose of an inhaled glucocorticoid, as assessed by measuring the morning peak expiratory flow (PEF), with a mean difference of 25.8 liters per minute (P<0.001) and superiority in most secondary outcomes, including evening PEF, with a difference of 35.3 liters per minute (P<0.001); the proportion of asthma-control days, with a difference of 0.079 (P=0.01); the forced expiratory volume in 1 second (FEV1) before bronchodilation, with a difference of 0.10 liters (P=0.004); and daily symptom scores, with a difference of -0.11 points (P<0.001). The addition of tiotropium was also noninferior to the addition of salmeterol for all assessed outcomes and increased the prebronchodilator FEV1 more than did salmeterol, with a difference of 0.11 liters (P=0.003).

When added to an inhaled glucocorticoid, tiotropium improved symptoms and lung function in patients with inadequately controlled asthma. Its effects appeared to be equivalent to those with the addition of salmeterol. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT00565266.).

NEJM via Pubmed

Friday, December 10, 2010

mHealth, Mobile Health Apps Gets A Search Engine From Mimvi

SAN FRANCISCO, Dec. 2, 2010 (GLOBE NEWSWIRE) -- Mimvi, Inc. (OTCBB:MIMV - News), the world's largest pure-play search, discovery and recommendation engine for finding mobile apps (or applications), has announced the launch of a specialized search and discovery engine for health-related mobile apps. The site, which is located at http://www.mimvi.com/health, provides a unique platform for companies and consumers worldwide. It is available for license to any health-related organization and other strategic partners.
Industry experts are forecasting a revolution in health-related mobile apps. A recent study by the research2guidance group predicts that the mobile healthcare market will grow exponentially to reach over 500 million mobile users, or 30 percent of an estimated 1.4 billion smartphone subscribers worldwide by 2015. Bill Gates recently validated this opportunity at the mHealth Summit, a conference for companies involved in mobile technology and health. Mr. Gates was quoted as saying, "Diagnosis of malaria and TB will likely be the first ones you can assign a number to and say without this mobile phone app these people would have died."
Kasian Franks, Mimvi's Founder and CEO, reinforced these insights, "The benefits that mobile technologies and, specifically, apps bring to healthcare are tremendous. This "megatrend" will be driven by both healthcare professionals and consumers alike. The developments we have seen to date, encompassing everything from diabetes and cholesterol management to finding the nearest ER, merely represent the tip of the iceberg. In the future, we will see all kinds of health and wellness-related applications that will save millions of lives and millions of dollars--monies which can be funneled into future research and development, as opposed to feeding a bureaucratic machine." Franks continued, "The technology that lives inside mobile devices provides so many opportunities for future innovation in the healthcare world. Think about the possibilities that cameras, environmental sensors and GPS technologies can create in saving lives and helping people proactively manage their health."
Mimvi's proprietary search and recommendation engines provide more results with greater relevance across multiple platforms than any other player in the world today--a competitive advantage that Franks went on to emphasize in the context of health, "Mimvi Health is the only specialized search and recommendation engine for healthcare in the world today. This puts us in a unique position to maximize the business opportunities for all key stakeholders: advertisers, healthcare providers and developers. This sales funnel is further widened by our proprietary Amazon-like recommendation system which provides truly meaningful suggestions--a critical component in our value proposition and the mobile apps market as a whole."
The revenue opportunities in the mobile industry are significant. A new report from BIA/Kelsey shows that U.S. mobile advertising revenues will grow from $491 million in 2009 to $2.9 billion in 2014. Mr. Franks spoke further about Mimvi's revenue model, "Our revenue strategy will include different approaches, from proven revenue models such as sponsored search results to proprietary revenue --generating technologies we are developing which will facilitate financial transactions inside the apps themselves. We will share more on this front in due course."

Thursday, December 09, 2010

Schizophrenia (RG1678), Multiple Sclerosis (Ocrelizumab) Drugs By Roche Enter Phase III Of Clinical Trials.I

Roche Holding AG (ROG.VX) Thursday announced that drugs slated to treat diseases like schizophrenia, and multiple sclerosis will enter phase III of clinical trails and may submit applications for as many as 10 new drugs by the end of 2013. Roche is the world's biggest cancer drug maker and is seeking new paths outside the oncology arena to mitigate the effects of recent development setbacks. Avastin, the company’s top seller, failed in studies in prostate, stomach and early colorectal cancer.

Start of phase III programs for potential breakthrough therapies in schizophrenia and multiple sclerosis

Schizophrenia

Positive phase II proof-of-concept data with RG1678 in patients with predominantly negative symptoms of schizophrenia were recently presented at an international medical meeting3. Based on these promising results, a global phase III program has been initiated which includes a total of six studies investigating RG1678 in combination with standard of care antipsychotic drugs in patients with either negative symptoms4 or residual positive symptoms of schizophrenia5. Running the studies for both indications in parallel will allow a better understanding of the effect of RG1678 on a broad spectrum of symptoms and its value in the management of patients at different phases of their disease. The first patient was randomized into the phase III program in November 2010.
RG1678 is an investigational first-in-class glycine reuptake inhibitor that normalizes glutamate neurotransmission, thereby targeting an important pathway in the treatment of psychiatric disorders. By normalising glutamate neurotransmission in the brain, RG1678’s unique mode of action could also have valuable therapeutic applications in other psychiatric indications beyond schizophrenia.

Multiple sclerosis

Ocrelizumab, a humanized anti-CD20 antibody administered as a six-monthly infusion, demonstrated a highly significant reduction in disease activity as measured by brain lesions (96% for 2000mg and 89% for 600mg ocrelizumab dosing regimens) and relapse rate (73% for 2000mg and 80% for 600mg ocrelizumab at week 24) compared to placebo in a phase II study in relapsing-remitting multiple sclerosis (RRMS). The efficacy data, amongst the highest seen in a phase II RRMS study, were recently reported at the ECTRIMS conference. Based on these results, ocrelizumab will move into phase III studies in multiple sclerosis. Two studies will explore ocrelizumab’s efficacy in RRMS head-to-head versus interferon, the current standard of care, and one study will investigate the potential of ocrelizumab in patients with primary-progressive multiple sclerosis (PPMS).  Phase III studies for ocrelizumab will commence in the first quarter of 2011.
 Press Release by Roche

Monday, December 06, 2010

Clobazam Found To Be Positive In Adjunctive Treatment of Seizures Associated With Lennox-Gastaut Syndrome

Lundbeck A/S announced today at the 64th annual meeting of the American Epilepsy Society in San Antonio, Texas, that the study of clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome (LGS) to be positive.Two highest dosages of clobazam as add-on therapy achieved the primary endpoint with a statistically significant reduction in average weekly rate of drop seizures, compared with placebo.. 77.6 percent of patients who received high-dosage clobazam achieved a 50 percent or greater reduction in average weekly rate of drop seizures. Lundbeck anticipates NDA submission by year-end after which the agency's confirmation of receipt of the submission will be awaited. ClinicalTrials.gov also lists this as the Phase III study of the Clobazam's effectiveness.

H. Lundbeck A/S (Lundbeck) today presented positive data from its pivotal phase III study to determine the efficacy and safety profiles of the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome (LGS). In the study, clobazam met its primary efficacy endpoint and was further supported by several key secondary efficacy endpoints.1 LGS is a rare and severe form of epilepsy that is typically diagnosed in childhood and persists into adulthood.2,3 Results from this largest clinical trial to date in LGS patients were presented at the 64th annual meeting of the American Epilepsy Society in San Antonio, Texas (Poster No. 1.283).1,4
This prospective, double-blind, placebo controlled study randomized 238 patients diagnosed with LGS to one of three different dosages of clobazam or placebo. Efficacy analyses were done for the modified intent to treat population (mITT), which included all randomized patients who had baseline data, at least one dose of study drug and at least one daily seizure measurement during the maintenance period (N=217).1
Data from the study's primary endpoint showed that the high (1.0 mg/kg/day; N=49) and medium (0.5 mg/kg/day; N=58) dosages of clobazam, evaluated versus placebo (N=57), met a robust statistically significant (p≤0.01) reduction in the average weekly rate of drop seizures from the 4-week baseline period compared to the 12-week maintenance period. Patients in the high-dosage clobazam group achieved a mean decrease in average weekly rate of drop seizures of 68.3 percent (p<0.0001 vs. placebo) while those in the medium-dosage arm had an average decrease of 49.4 percent (p=0.0015 vs. placebo).1
A secondary endpoint of the study was responder rates. For each group treated with one of the three different dosages of clobazam, the percentage of patients with a decrease in average weekly rate of drop seizures of ≥25%, ≥50%, ≥75% or 100% from baseline to the maintenance period was compared to placebo. Among patients in the high-dosage arm, 77.6 percent had a 50 percent or greater reduction (p<0.01); 63.3 percent had a 75 percent or greater reduction (p<0.01); and 24.5 percent achieved 100 percent reduction. Among patients in the medium-dosage arm, 58.6 percent had a 50 percent or greater reduction (p<0.05); 37.9 percent had a 75 percent or greater reduction (p<0.01); and 12.1 percent achieved 100 percent reduction. The logistic regression model used in this study was unable to provide valid p-value estimates for the 100 percent response thresholds due to the small number of patients enrolled in this group.1
"LGS is a devastating form of epilepsy associated with multiple types of seizures, including dangerous drop seizures which may cause falls that often result in injury. This can take a tremendous toll on even the strongest families," said Joan A. Conry, MD, professor of neurology at Children's National Medical Center in Washington, D.C., and a principal investigator in the study. "While several medications are approved in the U.S. for treatment of LGS, many patients continue to have seizures due to the intractable nature of the disease. The focus on this small patient population and the results of this study provide hope for LGS patients, their families and the medical community."
The study also evaluated the effect of clobazam in decreasing total seizures (drop and non-drop) as another key secondary endpoint. Robust statistical significance was observed in patients who received the high- and medium-dosage clobazam (p<0.01 in each arm versus placebo).1
In the study, the most common treatment emergent adverse events (AEs) included somnolence, lethargy, drooling, fever, and constipation. Serious AEs occurring in ≥2 patients were lobar pneumonia and pneumonia, which occurred in both clobazam and placebo treatment arms.1
"Lundbeck makes several treatment options available in the U.S. for people affected by epilepsy, and the development of clobazam for those with LGS represents our ongoing commitment to making a difference in the lives of those affected by rare and challenging seizure disorders," said Timothy M. Cunniff, PharmD, vice president of global regulatory affairs at Lundbeck. "We are encouraged by these phase III results and look forward to submitting an NDA very soon for clobazam."

About the Study
This phase III trial was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to assess the efficacy and safety of clobazam as adjunctive therapy in patients with LGS. Patient age ranged from 2-54, with a mean age at baseline of 12.4 years. Patients were included if they were being treated with one to three antiepileptic drugs (AEDs) at stable dosages for ≥30 days before screening and had ≥2 drop seizures per week during the 4-week baseline period.1
Prior to randomization, patients were stratified by weight (12.5 kg to ≤30 kg, >30 kg) and then randomized to placebo (N=59) or one of three dosages of clobazam: low (N=58 at 0.25 mg/kg/day up to a maximum of 10 mg per day), medium (N=62 at 0.5 mg/kg/day; maximum daily dosage of 20 mg per day), and high (N=59 at 1.0 mg/kg/day; maximum daily dosage of 40 mg). Of 238 patients randomized, a total of 217 comprised the modified intent to treat (mITT) population, which included all randomized patients who had baseline data, ≥1 dose of study drug, and ≥1 daily seizure measurement during the maintenance period. A total of 177 patients completed the study. Statistical significance for the primary efficacy endpoint was prespecified as p≤0.01 and considered robust statistical evidence in a single multi-center study, and p≤0.05 for secondary measures.1

About Clobazam
Clobazam is a 1,5-benzodiazepine that potentiates the inhibitory action of gamma-aminobutyric acid (GABA) by binding to GABA-A receptors.5,6 Additionally, research has identified three subtypes of the benzodiazepine omega receptor (ω).5 Diffusely distributed throughout the CNS, these ω receptors demonstrate a variety of pharmacological effects.6 In non-clinical studies, clobazam was shown to have higher affinity for the ω2 compared to the ω1 receptor.5 The precise mechanism of action by which clobazam exerts its antiepileptic effects is unknown.
The current study is part of a clinical development program to obtain FDA approval for clobazam as adjunctive treatment for patients with LGS. Clobazam is marketed outside of the U.S. in more than 100 countries under various brand names, including Frisium® or Urbanyl®. Brand names listed are property of their owners
Press release

Wednesday, December 01, 2010

Merck Is Ending The Isentress Phase III study, As The Drug Fails Once-a-day Treatment

 Based on the initial results of the study, which failed disappointingly, Merck the the U.S. based drugmaker announced that it was ending the Phase III study, which could have paved the way for wider use among previously untreated HIV or AIDS patients. Isentress is a leading drug for Merck and it is also one of the  fastest-growing drugs treating HIV-1 patients  . Its sales in the third quarter was $278 million, putting it on track to become a $1 billion-a-year drug for the company. Some analysts have predicted the drug to bring in 2 Billion annually by 2015.
Merck stocks took a bit of dive after the announcement. 
Following is the press release by Merck
WHITEHOUSE STATION, N.J., Nov. 29, 2010 - Merck today reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naïve adult patients infected with HIV-1. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults. In the study, although the treatment regimen that included ISENTRESS once daily enabled more than 80 percent of patients to achieve viral suppression, ISENTRESS once daily did not demonstrate non-inferiority to the treatment regimen that included ISENTRESS twice daily. Merck said that based on the initial results and following the recommendation of an independent Data Monitoring Committee, Merck will end the study. Merck is notifying clinical investigators of this decision this week and is recommending that patients enrolled in the once-daily dosing arm of the study be switched to ISENTRESS twice daily, the FDA-approved dose. Results from this study will be submitted for presentation at an appropriate scientific meeting in 2011.
This Phase III study evaluated the safety and efficacy of an investigational once-daily dose of raltegravir (800 mg once daily) versus the approved twice-daily dose (400 mg twice daily), each given in combination with a once-daily fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate, in adult treatment-naïve HIV-1-infected patients. In this study, 775 patients were randomized, and 770 patients received study drug and are included in the current analyses. After 48 weeks in the study, 83.2 percent (n=318/382) of patients receiving the regimen including ISENTRESS once daily achieved undetectable viral levels (HIV-RNA <50 copies/mL), compared to 88.9 percent (n=343/386) of patients receiving the regimen including ISENTRESS twice daily. The treatment difference between the 800 mg once daily group and 400 mg twice daily group was -5.7 percent, with an associated 95 percent confidence interval (CI) of (-10.7 percent, -0.83 percent). The difference did not meet the pre-defined statistical criteria for non-inferiority.
The overall treatment difference observed between the once-daily and twice-daily groups was primarily due to results in patients with high viral load. Among patients with more than 100,000 copies/mL of HIV-RNA, 74.3 percent (n=113/152) of those in the once-daily group achieved viral suppression compared to 84.2 percent (n=128/152) of those in the twice-daily group. The safety and tolerability profiles of the two regimens were similar in the study, and were consistent with current labeling for ISENTRESS.
About ISENTRESS
ISENTRESS is Merck's integrase inhibitor for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adult patients. ISENTRESS currently is the only approved integrase inhibitor for the treatment of HIV-1. The label for ISENTRESS is based on analyses of plasma HIV-1 RNA levels through 96 weeks in three double-blind controlled clinical studies of ISENTRESS. Two of these studies were conducted in clinically advanced, three-class antiretroviral (ARV) [non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor (PI)] treatment-experienced adults and one was conducted in treatment-naïve adults. The safety and efficacy of ISENTRESS have not been established in pediatric patients. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response.
ISENTRESS is the first medicine to be approved in a class of antiretroviral drugs called integrase inhibitors. ISENTRESS works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme and has demonstrated rapid antiviral activity. Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells. Other HIV-1 drugs in use inhibit two other enzymes critical to the HIV-1 replication process – protease and reverse transcriptase – but ISENTRESS is the only approved drug that inhibits the integrase enzyme. ISENTRESS is now approved in more than 90 countries worldwide. Merck is continuing to move forward with filings in additional countries around the world for use of ISENTRESS in both treatment-experienced and treatment-naïve HIV-infected patients.
Important safety information about ISENTRESS
ISENTRESS does not cure HIV or AIDS and does not prevent passing HIV to others. Healthcare providers should know that immune reconstitution syndrome has been reported in patients treated with ARV therapy, which may necessitate further evaluation and treatment.
Creatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and rhabdomyolysis have been reported. ISENTRESS should be used with caution in patients at increased risk of myopathy or rhabdomyolysis, such as patients receiving concomitant medication known to cause these conditions.
The most commonly reported drug-related adverse event (AE) of moderate to severe intensity that occurred in greater than or equal to 2 percent of patients and at a higher incidence than efavirenz in treatment-naïve patients receiving ISENTRESS was insomnia (4 percent versus 3 percent, respectively).
The most commonly reported (greater than or equal to 2 percent in either treatment group) drug-related clinical AE of moderate or severe intensity in treatment-experienced patients receiving ISENTRESS and at a higher rate compared to placebo was headache (2 percent vs. less than 1 percent) for ISENTRESS plus optimized background therapy (OBT) and placebo plus OBT, respectively.
In treatment-experienced patients, rash occurred more often in patients taking ISENTRESS and darunavir together than with either drug separately. Rashes were mild to moderate in severity and did not limit therapy. There were no discontinuations due to rash.
Dosing and administration
ISENTRESS is a single 400 mg tablet taken twice daily without regard to food. The dose of ISENTRESS should be increased during coadministration with rifampin to 800 mg twice daily.
Drug interactions
Co administration with strong inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 may reduce plasma concentrations of ISENTRESS. Rifampin, a strong inducer of (UGT) 1A1 reduces plasma concentrations of ISENTRESS. Based on the results of drug interaction studies and the clinical trials data, no dose adjustment of ISENTRESS is required when co administered with other ARV agents. Also, preclinical studies show that ISENTRESS is not metabolized by cytochrome P450 enzymes.
For more information, visit www.merck.com.

Monday, November 29, 2010

Dietary Reference Intakes for Calcium and Vitamin D, A New Report

The report “Dietary Reference Intakes for Calcium and Vitamin D” will be released to the public on November 30, 2010 at 10 am Eastern. The report release will be broadcast via live video webcast. 
If you like to watch the webcast, you need to register and that could be done by following this link, 'Register for this Meeting' The webcast will also be made available for viewing online about a week after the release.
At the time of the release, it will be possible to view the report online at www.iom.edu/vitamind or by linking to the website of the National Academies Press (www.nap.edu).  The report will also be available for purchase as hardcopy or as a PDF from the National Academies Press.
The last recommended level for those two nutrients was made in 1997 and since then various studies have found many benefits of Vitamin D and also have linked the deficiency of it to higher risk of cancer, cardiovascular disease, depression, infectious disease and other ailments.
With the push from various quarters like supplement makers, it is possible that the Institute of Medicine will raise the “dietary reference intake’’ for vitamin D. The current recommendations are 200 international units for people 50 and younger; 400 I.U. for those aged 51 to 70; and 600 I.U. for those 71 and above.
Then why is Calcium there? It is because one of the main roles of vitamin D is to help maintain the right levels of calcium in our bodies, therefor both of them are often considered together.
Institute of Medicine via NYT

Friday, November 19, 2010

Xanodyne Pharmaceuticals, Inc. Pulls Darvon® and Darvocet-N® Products

Xanodyne Pharmaceuticals Inc., the manufacturer of Darvon and Darvocet-N, widely used painkillers in the U.S. taking the products off the market because of a new study linking the active ingredient in the drugs to serious and sometimes fatal heart rhythm abnormalities.
The drug maker initiated the ban at the request of the Food and Drug Administration, which also asked makers of generic versions of the drugs' core compound, propoxyphene, to stop selling it in the U.S.
Following is the press release;

NEWPORT, Kentucky -- Xanodyne Pharmaceuticals, Inc. announced today that the company will voluntarily withdraw its Darvon®, Darvon-N®, and Darvocet-N® products from the U.S. market in consultation with the U.S. Food and Drug Administration (FDA).
This withdrawal is part of a market-wide withdrawal applying to all propoxyphene-containing products, affecting branded and generic pharmaceutical companies and a number of products on the market. 
Propoxyphene is a mild opiate used for the treatment of mild-to-moderate pain and has been on the U.S. market for the last 50 years.
On January 30, 2009, a meeting of the FDA Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee was convened to review the efficacy and safety of propoxyphene-containing products.  Following that meeting, Xanodyne agreed to work together with the FDA, and took a number of steps including developing a patient medication guide, strengthening several of the warnings in the product labeling, and conducting a clinical study to assess the maximum tolerated dose and effects of propoxyphene on cardiac conduction.
As a result of the availability and ongoing analysis of drug safety surveillance data and developing clinical information about the effects of propoxyphene on cardiac conduction, the FDA has determined that the benefits of propoxyphene-containing products no longer outweigh the potential risks.  Patients should consult their physicians for instructions on how to safely transition to appropriate alternatives.  For further information, patients can call Xanodyne’s medical information line in the United States at 1 (877) 773 7793 or visit www.xanodyne.com.
Contact:
Josh Galper
Orrick, Herrington & Sutcliffe LLP
202 339 8468
Jgalper@orrick.com

Thursday, November 18, 2010

Cardinal Health to buy NY pharma distributor Kinray for $1.3 Billion

DUBLIN, Ohio, Nov. 18, 2010 /PRNewswire-FirstCall/ -- Cardinal Health (NYSE: CAH) today announced plans to acquire Kinray, Inc., a leading pharmaceutical distributor serving the New York metropolitan area, for $1.3 billion in an all-cash transaction that will significantly expand its ability to serve retail independent pharmacies in the northeastern United States.
Cardinal Health expects the transaction to be neutral to slightly accretive to non-GAAP earnings in fiscal 2011, depending on the timing of the closing. The company estimates accretion in fiscal 2012 of at least $0.12 in non-GAAP earnings per share from continuing operations(1), including the impact of amortization of intangibles. This estimate is dependent on the timing of the closing and final valuation of intangibles.
"Adding Kinray to the Cardinal Health Pharmaceutical Segment portfolio will enable us to build on our increasing presence in community pharmacy and accelerate our growth in this important channel," said George Barrett, chairman and chief executive officer of Cardinal Health. "We are excited to have the Kinray employees join the Cardinal Health family, and we look forward to their contributions. Kinray has a long-standing service tradition with its customers. We intend to continue that tradition, utilizing its customer expertise and Whitestone distribution facility, while creating additional value for its customers through branded pharmaceutical programs, inventory and pharmacy management tools and Cardinal Health's extensive generic drug program."
With annual sales in excess of $3.5 billion, Kinray currently serves more than 2,000 retail independent pharmacy customers as a distributor of both branded and generic pharmaceuticals. The company primarily serves the New York metropolitan area and will establish a stronger platform for Cardinal Health in the northeastern U.S. The addition of Kinray will continue to diversify and broaden Cardinal Health's customer mix by increasing the company's retail independent pharmacy base by 40 percent to approximately 7,000 total customers. Subject to customary closing conditions and regulatory approvals, Cardinal Health plans to complete the transaction by the end of the calendar year or early in 2011.
"Joining forces with Cardinal Health supports Kinray's mission to help retail independent pharmacies serve as an integral provider of care for our evolving health care system," said Stewart Rahr, president and chief executive officer of Kinray. "The combination of Kinray's distribution model with the benefits of the value-added services offered by Cardinal Health will benefit our customers, making them even more efficient and successful in caring for their patients. It also provides our people with the opportunity to join one of the world's premier health care companies – one that understands the value we bring to the retail independent pharmacies we serve."
After the transaction is complete, Kinray customers will be able to tap into a leading line of service offerings from Cardinal Health including its SOURCE(SM) Generics program and additional tools that help improve the back office efficiency of retail pharmacies, including inventory management tools, reimbursement services, managed care contracting services, Specialized Care Centers and local store marketing programs.
Cardinal Health

Saturday, November 13, 2010

Medicare Open Enrollment Open Now.

Medicare Open Enrollment opens up in every fall, this fall is no difference. Follow the link to see a video and resource links for help with Medicare Open Enrollment, which will be open from November 15 to December 31.

Oncowikia Blog: Medicare Open Enrollment Open From November 15 To December 31 2010

Tuesday, November 09, 2010

National Diabetes Month, November! Do Something To Stop, Prevent Diabetes.

November is the American Diabetes Month, even though everyone should be aware of the decease that affects many a people all over the world. It is preventable, or could be delayed with right amount of work. The Diabetes.org is carrying out a campaign to make people aware of diabetes and ways and means to prevent it.
In series of articles and bloggings and may other activities, we too can let as many people know about this decease.
Here is an interview by Dayle with celebrity Bret Michaels,who also suffer from type 1 diabetes;

You’ve had a very busy and extremely successful year so far – what inspired you to add representing American Diabetes Month as the Face of Diabetes to everything else?
This cause is so important to me. Being diagnosed with type 1 diabetes at such a young age had a profound impact on me – it’s a huge part of who I am, so of course this is something I feel incredibly passionate about.

Diabetes doesn’t have to derail your dreams.  I’m so proud to be the “Face of Diabetes;” if my work can remind other people who are struggling with the disease that it is possible to manage diabetes and still live an amazing life, then I’m happy.
What’s your daily diabetes routine look like?
Every day is a battle. You have to wake up and say to yourself, ‘I accept that I have diabetes, and I’m not going to let it run my entire life.’ It’s a fine line, a catch-22, a balancing act. I work to enjoy my life like a regular human being and at the same time keep my blood sugar levels as decent as possible.

Do you find it harder to maintain when you’re on tour?

For sure, being on the road for months on end can mess with my routine. I test my blood sugar about six to eight times a day and eat smaller meals all day long to keep my blood sugar even.
Did you ever struggle with how diabetes fits into your identity?  If so, how did you overcome this?

This is disease is something I’ve been struggling with for more than four decades.  Diabetes is undeniably a huge part of who I am and it is definitely something I’ve worked hard to come to grips with. At the same time, I’ve never let it limit me or hold me back. All I can do is take it one day at a time and be thankful for every day I handle successfully.
You were diagnosed at a young age – what do you remember?
I was six years old when I was diagnosed with diabetes; I remember I was in between kindergarten and first grade. It came on really quickly and I will never forget how extremely sick and dehydrated I was. Everything I drank or ate immediately came out of me. At  two or three in the morning my mom and dad took me to the Harrisburg hospital (in Harrisburg, PA) – the doctors in the emergency room knew what the problem was right off the bat; they recognized that it was type 1 diabetes immediately.
What do you wish someone had told you when you were first diagnosed? What would you say to kids who have just been diagnosed?
When I was first diagnosed I had no idea what was happening to me or going on inside my body. Before my parents took me to the hospital, my stomach was bloated and I was literally drinking almost a gallon of water at a time. Because my parents didn’t know what diabetes was, they were giving me soda to drink, which was not only dehydrating me more, but making my blood sugar go up twice as much. Learning more about the disease and how to keep your blood sugar stable is hugely important in living with the disease, so I would tell kids who have been diagnosed to definitely accumulate as much knowledge as possible about diabetes, just be aware and arm yourself with as much information as you can.
We just celebrated Halloween a few weeks ago, which can be tricky for kids with diabetes.  What was that like for you as a kid?  And, because we’re curious – what did you dress up as? (I’m secretly hoping David Cassidy is an answer here…)
I love Halloween now with my daughters, and I loved it as a kid, too. Even without all the candy. Just dressing up and having a good time going out with all of my friends – for me that was what the holiday was all about.  And you know, I never dressed up as David Cassidy as a kid but maybe I should borrow your idea for next year, it might make a good costume…
Thanks so much for taking the time to share a little about you with us. We hope you have a very happy American Diabetes Month! Do you have any special activities planned for November to celebrate/acknowledge this?
This being American Diabetes Month, I’m trying to speak out about the disease as much as possible.  I really want to be a positive role model for others in the diabetes community who are suffering, so I’m going to stick to my daily routine, keep my blood sugar stable, serve as a positive role model, and take every opportunity to spread awareness about the disease.
Sounds like a great plan! If you could tell the world one thing about diabetes, what would it be?
Diabetes is a disease, yes, but it’s manageable one. You can have diabetes and still accomplish all kinds of unbelievable things. If I can help remind people of that, then I’m incredibly honored. If anything, diabetes is just a challenge to overcome – a prompt to be mindful of and grateful for my health, and a cue to dream bigger and do more.
Diabetes.org

Sunday, November 07, 2010

Terbinafine and Amitriptyline - Dry mouth, dizziness, and cardiac toxicity caused by prolonged increase in amitriptyline and nortriptyline (Pamelor) levels

Terbinafine and Amitriptyline

Affecting Drug 

D01BA02  Terbinafine

Effect

Augments

Affected Drug

N06AA09  Amitriptyline

Details

Dry mouth, dizziness, and cardiac toxicity caused by prolonged increase in amitriptyline and nortriptyline (Pamelor) levels

Evidence

Good

Cytochrome P450 enzymes are essential for the metabolism of many medications. Although this class has more than 50 enzymes, six of them metabolize 90 percent of drugs, with the two most significant enzymes being CYP3A4 and CYP2D6. Genetic variability (polymorphism) in these enzymes may influence a patient's response to commonly prescribed drug classes, including beta blockers and antidepressants. Cytochrome P450 enzymes can be inhibited or induced by drugs, resulting in clinically significant drug-drug interactions that can cause unanticipated adverse reactions or therapeutic failures. Interactions with warfarin, antidepressants, antiepileptic drugs, and statins often involve the cytochrome P450 enzymes. Knowledge of the most important drugs metabolized by cytochrome P450 enzymes, as well as the most potent inhibiting and inducing drugs, can help minimize the possibility of adverse drug reactions and interactions. Although genotype tests can determine if a patient has a specific enzyme polymorphism, it has not been determined if routine use of these tests will improve outcomes. 

Reference

Tuesday, November 02, 2010

oncowikia : Researchers Find A signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer.

oncowikia Blog: Pathway That Drives Spread of Pediatric Bone Cance...: "Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer...."

FDA Approves Avanir's NUDEXTA, For Treating PSEUDOBULBAR AFFECT

*NUEDEXTA IS FIRST AND ONLY FDA-APPROVED TREATMENT FOR PSEUDOBULBAR AFFECT*
*AVANIR TO HOST CONFERENCE CALL ON NOVEMBER 1, 2010 AT 8:15 AM EASTERN TIME*

ALISO VIEJO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.
NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state.
"The FDA approval of NUEDEXTA marks an important milestone for people living with PBA, an under-recognized and debilitating neurologic condition," said Keith Katkin, president and chief executive officer of Avanir. "The approval of NUEDEXTA also marks AVANIR's transition toward becoming a commercial enterprise, ready to support the successful launch of the first FDA-approved treatment for PBA. We expect that NUEDEXTA will be available by prescription during the first quarter of 2011."
"This FDA approval represents a significant step forward for people who live with the debilitating effects of PBA," said Dr. Nicholas LaRocca, Vice President of Healthcare Delivery and Policy Research at the National MS Society. "For people who experience unexplained bouts of inappropriate laughing or crying, this new therapy has the potential to substantially help both them and their families."
"Today's approval of NUEDEXTA is a testament to the conviction of the patients and researchers who participated in our studies and represents over 10 years of research and development by our dedicated employees," said Randall Kaye, MD, Chief Medical Officer, AVANIR Pharmaceuticals. "We are very pleased to bring the first proven treatment option to the many patients in the U.S. living with PBA. I would like to thank FDA for working closely with us to make NUEDEXTA available."
"PBA is a disabling neurologic condition commonly found in patients with underlying neurologic diseases or injuries. These patients frequently experience embarrassment due to their unpredictable emotional outbursts, leading to disruption of their interpersonal relationships and social isolation," said Erik P. Pioro, MD, PhD, FRCPC, Director of the Section for ALS and Related Disorders at the Cleveland Clinic in Cleveland, Ohio and an investigator in clinical studies evaluating NUEDEXTA. "As a physician who has cared for many patients with PBA, I am pleased that there is now a safe and effective treatment option for PBA that may help these patients regain more control over their daily lives and live with dignity."
NUEDEXTA is a first-in-class medication that acts on sigma-1 and NMDA receptors in the brain, although the exact mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.
The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.
Conference Call
AVANIR will hold a conference call and audio webcast on November 1, 2010 at 8:15 a.m. Eastern time. To participate in the conference call, please dial 877-558-3407 (domestic) or 706-679-1941 (international) and reference the access code 22130601. A live audio webcast of the conference call will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the conference call will be available on the Company's website for 30 days.

Hi-Tech Life Styles Like Games, Texting Are Affecting Childrens Sleep, Health, Study Finds.

With the new hi-tech toys available in every home and every bedroom, children are playing games, watch TV, Texting and emailing long after bedtime according to a new study. These children develop dyslexic learning problems the following morning due to lack of sleep..
The study covered 40 students sent, on average, 33.5 texts or emails per school night after bedtime -- from 10 minutes to four hours after ''lights out,"  says researcher  Peter G. Polos, MD, attending  physician at the JFK Medical Center sleep laboratory in Edison, N.J.
He is due to present his findings this week at CHEST 2010, the annual meeting of the American College of Chest Physicians in Vancouver, British Columbia.
''It reaffirms my suspicion that the availability of these media to children can or will have a significant impact on their quality and quantity of sleep, Most of the 40 students reported either learning, behavioral, or cognitive issues. This [emailing and texting] is more stimulatory than television, I think," Polos told WebMD.

Dr. Polos and his colleagues surveyed the students, ages 8 to 22, with an average age of 14.5, who had come to the sleep clinic on their sleep habits. More than 77% of the students had persistent problems getting to sleep, he says. The team found boys are more likely to surf the Internet and play games online after bedtime, while girls are more likely to use their cell phone or send text messages.
The 33.5 emails and texts were sent to about four people during a school night.
The average number of awakenings per night due to media was one.
The average number  of  texts sent per month including weekend nights after bedtime was 3,404 per person.
The older the student, the more time he or she was likely to spend texting and emailing after bedtime.
Polos found. “That number reflects a portion of children who were excessively using the media.”
 
The pilot study, Polos says, suggests that bedtime media use "may have an adverse impact on sleep hygiene and daytime function which may be significant." The study didn't prove cause and effect between late-night texting and emailing and impairments in daytime functioning, Polos says. But, he says, a student with a learning disability, for instance, who is also sleepy probably won't be performing at school at his best.
So make kids bedrooms a electronic free zone and make the healthy.

  • Make the bedroom a technology-free zone, with no TVs, cellphones, iPods, computers or video games

  • Turn off electronic devices at least half an hour before bed

  • Friday, October 29, 2010

    LATUDA® (lurasidone HCL) for the Treatment of Patients with Schizophrenia Approved By FDA.

    MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has approved LATUDA® (lurasidone HCl) tablets for the treatment of schizophrenia. LATUDA is an oral, once-daily atypical antipsychotic, offering a first-line treatment option for patients with schizophrenia and is expected to be available in the U.S. during the first quarter of 2011.
    “LATUDA marks both a significant achievement for our company as well as the first FDA approval for Sunovion since becoming the U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd.,” said Masayo Tada, president and chief executive officer, Dainippon Sumitomo Pharma Co., Ltd. “With this approval, we’ve taken another big step towards becoming a truly competitive global company by enhancing the presence of Sunovion in the United States.”
    Schizophrenia is a chronic, disabling and serious brain disorder that affects approximately 2.4 million American adults or 1 in 100 people. Schizophrenia is characterized by symptoms such as hallucinations, delusions, disorganized thinking, lack of emotion, lack of energy, as well as problems with memory, attention and the ability to plan, organize and make decisions.
    “LATUDA offers a once-daily treatment option that has been shown to be both effective and tolerable, adding to psychiatrists’ ability to address the challenging therapeutic needs of people with schizophrenia,” said Antony Loebel, M.D., executive vice president, Clinical Research and Medical Affairs at Sunovion Pharmaceuticals Inc.
    The FDA reviewed data from more than 40 clinical trials involving approximately 2,700 LATUDA-treated adult subjects. The efficacy of LATUDA for the treatment of schizophrenia was established in four pivotal, 6-week placebo-controlled clinical trials. In these studies, LATUDA demonstrated significantly greater improvement versus placebo on the primary efficacy measures [the Positive and Negative Syndrome Scale (PANSS) total score and the Brief Psychiatric Rating Scale-derived from PANSS (BPRSd)] at study endpoint. A total of five clinical trials contributed to the understanding of the tolerability and safety profile of LATUDA.
    “Schizophrenia is associated with severe and debilitating symptoms such as delusions, hallucinations and disorganized thinking, and it can often have a devastating impact on patients and their families,” said Herbert Meltzer, M.D., professor of psychiatry and pharmacology, Vanderbilt University School of Medicine. “Based on the results of the clinical trials, LATUDA represents an important addition to the treatment of schizophrenia.”

    Diet Pill Qnexa Rejected By FDA Citing Health Risks

    Food and Drug Administration, FDA have decided not to approve an experimental diet drug, Qnexa. Vivus Inc., the manufacturer of the drug, announced in a press statement that the FDA declined to approve the drug in its present form. The agency asked for more study results and additional information on its possible health risks, including suicidal thoughts, heart palpitations, memory lapses and birth defects.

    With obesity affecting many people across the globe, pressure to find a drug is high and this is the second drug to be rejected by FDA within a week. Last week FDA rejected drug lorcaserin, by Arena Pharmaceuticals.
    MOUNTAIN VIEW, Calif., Oct 28, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA(R) (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form. The application seeks the approval to market QNEXA as an oral, once-a-day formulation for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.

    The CRL included the following areas: clinical, labeling, REMS, safety update, and drug scheduling.

    In the clinical section of the CRL, the FDA requested a comprehensive assessment of topiramate's and phentermine/topiramate's teratogenic potential. This will include a detailed plan and strategy to evaluate and mitigate the potential teratogenic risks in women of childbearing potential taking the drug for the treatment of obesity. In addition, the FDA asked VIVUS to provide evidence that the elevation in heart rate associated with phentermine/topiramate does not increase the risk for major adverse cardiovascular events.

    The FDA requested that VIVUS formally submit the results from the already completed SEQUEL study (OB-305), a 52-week extension study for a subset of 675 patients who completed the previously reported 56-week CONQUER study. Top-line results from the two-year SEQUEL study were announced by VIVUS on September 21, 2010 and a final study report is being prepared for submission to the NDA.

    The FDA reserved the right to comment further on proposed labeling. On REMS, the FDA requested that a discussion of an already submitted REMS plan be continued after the written response from VIVUS has been submitted. The agency also requested a safety update of any new adverse events be submitted to the NDA. Finally, the FDA stated that if approved, phentermine/topiramate would be a Schedule IV drug due to the phentermine component.

    As part of the written response, VIVUS plans to compile analyses integrating existing nonclinical and clinical data to provide a comprehensive assessment of the teratogenic potential of topiramate. In addition, VIVUS plans to provide several new analyses to demonstrate QNEXA does not increase the risk for major cardiovascular events, which would include data from our OB-305 and OB-204 studies. In the CRL, no new clinical studies were requested; however, in the event that any of the FDA concerns are not alleviated, additional clinical studies may be required.

    "We remain confident in the efficacy and safety profile of QNEXA demonstrated in the clinical development program and look forward to continue working with the FDA towards the approval for the treatment of obesity," said Leland Wilson, chief executive officer of VIVUS. "We are preparing a comprehensive response to the CRL for submission to the FDA in approximately six weeks."

    Tuesday, October 26, 2010

    Medicare Explained!

    Do you know about Medicare and what does it cost? Do you know what medicare cover? Medicare has two parts Medicare Part A and Medicare Part B.
    Medicare Part A:  Hospital Insurance and helps to pay for hospital, hospice and home health care.
    Medicare Part B:  Medical Insurance and and helps pay for doctors, outpatient care, and other medical services.
    Both are very important and depending on ones age, social security status and of course timely application for Medicare.
    One retirement planner asked  Charles Schwab's  Ask Carrie the following question;


    I'm turning 65 next year. I’m still working and plan to continue for at least a couple more years, so I won't yet file for Social Security. I do, however, want to get Medicare. What do I need to do to make sure I get the right coverage?
    I think the answers were great and everyone should read. Take care with Medicare.
    Ask Carrie

    Tuesday, October 12, 2010

    oncowikia on Cancer And You,Wordpress, Keywords...

    oncowikia Blog: Cancer And You, Source For Cancer Related Keywords...: "Iwas checking on ONCOWIKIA on search engines, I found that Cancer and You site listed just below my post on Meddesktop, ONCOWIKIA and ONCOSE..."

    Monday, October 11, 2010

    ONCOWIKIA and ONCOSEMANTIC, Will Be Caring For Cancer.

    cancer (KAN-ser) or malignancy is a term for diseases in which abnormal cells divide without control and can invade nearby tissues. Cancer cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of cancer.
    Carcinoma is a cancer that begins in the skin or in tissues that line or cover internal organs.
    Sarcoma is a cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue.
    Leukemia is a cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood.
    Lymphoma and multiple myeloma are cancers that begin in the cells of the immune system.
    Central nervous system cancers are cancers that begin in the tissues of the brain and spinal cord.

    The ONCOWIKIA will cover every and each information, possible about cancer or malignancy with the help of health care professionals. We will also cover the treatment, treatment process and related medicines and regiments will all be a part. These information will also be provided through ONCOSEMANTIC as a social media hub related to cancer information and avenues to fend it.
    Some of the cancer types are;

        * Bladder cancer
        * Bone cancer
        * Breast cancer
        * CNS/Brain cancer
        * Colon and Rectum cancer
        * Endocrine cancer
        * Esophagus cancer
        * GYN (Non-Ovary) cancer
        * GYN (Ovary) cancer
        * Head and Neck cancer
        * HIV-Related Cancers
        * Hodgkin's Lymphoma cancer
        * Kidney (Renal Cell) cancer
        * Leukemia cancer
        * Liver and Bile Duct cancer
        * Lung cancer
        * Multiple Myeloma cancer
        * Myelodysplastic Syndrome cancer
        * Myeloproliferative Diseases cancer
        * Non-Hodgkin's Lymphoma cancer
        * Pancreas cancer
        * Pediatric Cancers
        * Prostate cancer
        * Rare Cancers
        * Skin (Melanoma) cancer
        * Skin (Non-Melanoma) cancer
        * Soft-Tissue Sarcoma cancer
        * Stomach cancer
        * Testicle cancer
    and many more specific cancer information will be disseminated via ONCOWIKIA and ONCOSEMANTIC sites..  
    For now you will find ONCOWIKIA Blog providing information and the progress of the development of the sites.

    IZDIO.COM The SOurce Of ICD-10 Coding Informtion.

    IZDIO.COM released following information on their first and foremost activity, Providing ICD-10_PCS information to patients, Healthcare workers, Doctors ,Nurses or anyone seeking ICD-10 data and information;
    THE INTERNATIONAL CLASSIFICATION OF DISEASES Tenth Revision Procedure Coding System (ICD-10-PCS) was created to accompany the World Health Organization’s (WHO) ICD-10 diagnosis classification. The new procedure coding system was developed to replace ICD-9-CM procedure codes for reporting inpatient procedures.
    Unlike the ICD-9-CM classification, ICD-10-PCS was designed to enable each code to have a standard structure and be very descriptive, and yet flexible enough to accommodate future needs. Information about the structure, organization, and application of ICD-10-PCS codes, along with reference material for coding with ICD-10-PCS, is provided in this manual.
    IZDIO, and IZDIO.COM will work on the following parts ofICD-10-PCS:
    ◆What is ICD-10-PCS?
    ◆ICD-10-PCS code structure
    ◆ICD-10-PCS system organization
    ◆ICD-10-PCS design
    ◆ICD-10-PCS additional characteristics
    ◆ICD-10-PCS applications
    In addition, we will present more specific information on coding with ICD-10-PCS as the site forms.

    Friday, October 08, 2010

    Abbott Laboratories agrees to withdraw its obesity drug Meridia (sibutramine)

    Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events
    [Posted 10/08/2010] Abbott Laboratories agrees to withdraw its obesity drug Meridia
    FDA Earlier Alerted Public about the fact;
    "Meridia (sibutramine) increases their risk of heart attack and stroke in patients with a history of cardiovascular disease"

    “Meridia’s continued availability is not justified when you compare the very modest weight loss that people achieve on this drug to their risk of heart attack or stroke,” said John Jenkins, M.D., director of the Office of New Drugs in the FDA’s Center for Drug Evaluation and Research (CDER). “Physicians are advised to stop prescribing Meridia to their patients and patients should stop taking this medication. Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs.”

    AUDIENCE: Primary Care, Consumers
    ISSUE: Abbott Laboratories and FDA notified healthcare professionals and patients about the voluntary withdrawal of Meridia (sibutramine), an obesity drug, from the U.S. market because of clinical trial data indicating an increased risk of heart attack and stroke.
    BACKGROUND: Meridia was approved November 1997 for weight loss and maintenance of weight loss in obese people, as well as in certain overweight people with other risks for heart disease. The approval was based on clinical data showing that more people receiving sibutramine lost at least 5 percent of their body weight than people on placebo who relied on diet and exercise alone. FDA has now requested market withdrawal after reviewing data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT). SCOUT is part of a postmarket requirement to look at cardiovascular safety of sibutramine after the European approval of the drug. The trial demonstrated a 16 percent increase in the risk of serious heart events, including non-fatal heart attack, non-fatal stroke, the need to be resuscitated once the heart stopped, and death, in a group of patients given sibutramine compared with another given placebo. There was a small difference in weight loss between the placebo group and the group that received sibutramine.
    RECOMMENDATION: Physicians are advised to stop prescribing Meridia to their patients, and patients should stop taking this medication. Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs.

    [10/08/2010 - Drug Safety Communication - FDA]
    [10/08/2010 - Questions and Answers - FDA][10/08/2010 - News Release - FDA]
    Previous MedWatch Alert:
    [01/21/2010 - Meridia (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review]

    Potentially harmful stimulant sibutramine found in Beautiful Health Inc's Slimming Beauty Bitter Orange Slimming Capsules.

    [Posted 10/08/2010] Potentially harmful stimulant found in Slimming Beauty capsules
    AUDIENCE: Consumers
    ISSUE: FDA notified consumers that Slimming Beauty Bitter Orange Slimming Capsules contain the active pharmaceutical ingredient sibutramine, a prescription-only drug which is a stimulant. Sibutramine is not listed on the product label and could harm consumers, especially those with cardiovascular conditions, because it can lead to elevated blood pressure, stroke, and heart attack. Consumers who are otherwise healthy and who take the amount of sibutramine found in Slimming Beauty capsules can experience anxiety, nausea, heart palpitations, a racing heart, insomnia, and elevated blood pressure. Sibutramine also may interact with other medications and can cause serious side effects.
    BACKGROUND: Slimming Beauty is being sold over the Internet by Beautiful Health Inc., formerly LL Health and Beauty. Slimming Beauty sample packets also have been distributed by individuals at community events.
    RECOMMENDATION: Consumers should discontinue use immediately. The FDA News Release provides product photos.
    Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of this product to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
    • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
    • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

    Thursday, September 30, 2010

    HealthCare Droid From Panasonic Washes Hair Of Patients.

    Panasonic robot development engineer Tohru Nakamura displays a prototype model of hair-washing machine that makes 3D scanning of the user's head, shampoos and massages with 16 'fingers' at the annual Home care and Rehabilitation exhibition in Tokyo. -- PHOTO: AFP
    'With 16 fingers, the robot washes hair and rinses the shampoo bubbles with the dexterity of human fingers,' the company said in a statement.
    Panasonic unveiled on Thursday a robot who scans a client's head using 3D technology, then shampoos their hair and massages the scalp with 16 rubbery 'fingers'. The machine was developed to help the Japanese healthcare facilities now are filling with aging populace and diminishing healthcare personnel. The robot was at the annual Homecare and Rehabilitation exhibition in Tokyo.
    HCR 2010

    Wednesday, September 22, 2010

    Rogue Online Phamacies Taken To Court By Google.

    Google advertising is as wide as Google search and there will always be rogues playing for their place. Some times we wonder how come these spammy ads appear on our sites, specially from Google, endangering lives with unauthorized pharmaceuticals sales, which can be dangerous without the right prescription.
    Google is telling us that it has been fighting these rogues with extensive verification procedures, automated keyword blocking, to changing our ads policies but still those bad people managed to sneak in.
    So Google has;
    " filed a civil lawsuit in federal court against advertisers we believe have deliberately broken our rules. Litigation of this kind should act as a serious deterrent to anyone thinking about circumventing our policies to advertise illegally on Google. As we identify additional bad actors, we will add them to the lawsuit. Rogue pharmacies are bad for our users, for legitimate online pharmacies and for the entire e-commerce industry—so we are going to keep investing time and money to stop these kinds of harmful practices."
    Good one Google, How about those spammers with similar informatio asking us to visit those sites. You can find them in any GMail Spam folder! :)

    Official Google Blog: Taking rogue pharmacies to court

    Friday, September 17, 2010

    FDA Extends The Review Of Avastin For Breast Cancer By Another 3 Months.

    Avastin, a cancer fighting drug is under examination and FDA has announced today that the review will be extended by another 90 days. The review is to decide if the drug should be used in treatment of breast Cancer. The expensive drug seem to have not worked very well on breast cancer patients.
    Avastin was approved by FDA in 2008 for breast cancer patients based on a trial. As a condition of approval, Roche, parent company of Genentech was required to conduct follow-up studies to demonstrate further the benefits of adding Avastin to conventional chemotherapy.In July an FDA advisory committee recommended the FDA, to revoke the Avastin's approval for breast cancer.

    If the FDA revokes the approval, it's believed insurance companies will stop paying for this drug, which could cost more than $8,000 a month. Only the very rich will be able to afford the treatment.

    Wellness, Fitness Features Enhances Google Health

    Google Health launched about two years ago, provide users to have their health record in one accessible place. Health Records on Google Health are protected and only available to approved entities to view digest and help the user, like personal physician or a doctor in distant land while you are holidaying.
    The new features on Google Health focuses on Wellness and fitness by adding new features and collaborating with industry leaders in providing additional services to Google Health users.
    The Google Health team has developed an easier-to-use dashboard that brings together even more of users health and wellness information in one place, making it easier to organize and act on that information.
    Users are now able to collect the data they need to track wellness, fitness goals and their progress with,
    Fitbit, maker of a wearable device that captures health and wellness data such as steps taken, calories burned and sleep quality
    CardioTrainer, one of the top mobile apps for tracking fitness activity and weight loss.

    The new design also brings user ability to take notes and keep a journal of their progress through health conditions or medications response.
    Google has also added more healthcare data providers, like Lucile Packard Children’s Hospital at Stanford, University of Pittsburgh Medical Center (UPMC) and Sharp HealthCare.
    Official Google Blog: A Google Health update

    an

    Friday, September 10, 2010

    Stand Up To Cancer

    There is no telling how much we help someone or ourselves, by standing up to cancer. I am working in the field, everyday, in the computing, moving vast data about cancer treatments leaves me in wonderment. I get frustrated everyday seeing how hospitals drug companies, treat people like money making machines.
    But I am now watching "Stand Up To Cancer" and gives me the strength to stand up, to cancer and all the evil. Just one gesture can change a lot!
    su2c
    Join Stand Up To Cancer You can donate with facebook credit.

    Thursday, August 26, 2010

    Huber Needles From Multi-Med, Inc., & Navilyst Medical Inc., Recalled

    AUDIENCE: Risk Manager, Surgery, Critical Care Medicine
    ISSUE: FDA notified healthcare professionals of the Class I Recall of certain Huber needles that were determined by FDA testing to produce cores when inserted into ports. Coring may lead to infection, damage or death of tissue, swelling, or other serious adverse health consequences, occurring as a result of the core travelling through blood vessels into the patient’s lungs. These issues may potentially cause death.
    BACKGROUND: Following hospital reports to the FDA of leakage after accessing the port with a Huber needle (labeled to be non-coring), FDA conducted its own laboratory testing of Huber needles from multiple manufacturers. Huber needles are safety needles used on vascular access ports implanted in patients in need of repeated intravenous therapy. A "coring" Huber needle could damage the implanted port by removing silicone slivers from the access membrane. The defect in the port as a result of coring can cause the ports to leak. The core can also potentially enter a patient’s body when the port is initially accessed if it is not flushed correctly.
    RECOMMENDATION: Clinicians should immediately discontinue use of the recalled products. If you must use the kit, consider using an alternative, unaffected non-coring needle if possible.
    Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
    • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
    • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
    [08/26/2010 - Recall Notice - FDA] See Below;
    Previous MedWatch Alert:
    [01/26/2010 - Recall Notice - FDA]

    Huber needles are safety needles used on vascular access ports implanted in patients in need of repeated intravenous therapy. A "coring" Huber needle could damage the implanted port by removing silicone slivers from the access membrane. The defect in the port as a result of coring can cause the ports to leak. The core can also potentially enter a patient’s body when the port is initially accessed if it is not flushed correctly. These issues may lead to the decreased effectiveness of the port, replacement of the port, infection, damage or death of tissue, swelling, or other serious adverse health consequences occurring as a result of the core travelling through blood vessels into the patient’s lungs. These issues may potentially cause death.
    Recall Class: Class I
    Date Recall Initiated: May 26, 2010
    Products:
    Multi-Med, Inc.
    • 22 Gauge x 1 inch straight Huber needles
      Model 10600218, Lot 9B020M.
    • 22 Gauge Right Angle x 1 inch Huber needles
      Model 10600219, Lot 9B017M
    These products were not sold individually; they were sold to Navilyst and packaged in certain lots of Vaxcel Implantable Vascular Access Systems. The Navilyst vascular access systems containing these defective needles can be identified in the list below.
    Navilyst Medical, Inc.*
    • Certain lots of Vaxcel Implantable Vascular Access Systems with PASV (Pressure Activated Safety Valve) Technology
    • Certain lots of Vaxcel Implantable Vascular Access Systems
    * Navilyst Medical Inc. bought Boston Scientific Oncology Division in 2008; therefore, some recalled Vaxcel Implantable Vascular Access Systems are labeled as Boston Scientific products.
    To find the complete list of products affected by this recall, see list below (Navilyst Medical, Inc. and Boston Scientific Vaxcel Implantable Vascular Access Systems Containing Huber Needles: Products Affected by the Class I Huber Needle Recall).
    The affected devices were manufactured from May 2, 2007 to May 1, 2010 and were distributed from May 2, 2007 to May 1, 2010.
    Use:
    Huber needles are used to access ports implanted under the skin of patients. These needles are intended to penetrate the port septum without cutting or dislodging any silicone cores (or slivers) from the ports into which they are inserted.
    Recalling Firms:
    Multi-Med, Inc.
    26 Victoria Ct.
    Keene NH 03431
    Navilyst Medical, Inc.
    10 Glens Falls Technical Park
    Glens Falls, New York 12801
    Reason for Recall:
    In September and November 2009, FDA sampled and tested Navilyst Medical, Inc. products containing Huber-style needles manufactured by Multi-Med, Inc. FDA testing determined that these needles “cored” in 23 to 86 percent of tests.
    Public Contact:Navilyst Medical Inc. may be contacted by phone at 1-800-833-9973, Monday through Friday, during the hours of 8:00 AM and 7:00 PM (Eastern Standard Time); and by FAX at 1-518-742-4450.
    Multi-Med Inc. representative Susan Starkey can be contacted by phone at 1-603-357-8733, Monday through Friday, from 8:00 to 5:00 PM (Eastern Standard Time) for instructions for disposition of the needles.
    FDA Districts: New York (Navilyst Medical, Inc.) and New England (Multi-Med, Inc.)
    FDA Comments:The company has advised:
    Distributors:
    • Immediately examine your inventory and quarantine product subject to therecall.
    • Identify customers that have received these needles and notify them at once of this product recall.
    Clinicians/Users:
    • Immediately discontinue use of the product.
    • If you must use the kit, consider using an alternative, unaffected non-coring needle if possible. However if you do not have an alternate and unaffected non-coring needle, consider performing the following flushing procedures of the port as recommended by the FDA:
      • Avoid flushing the syringe when initially confirming needle patency upon accessing the port. If the needle has cored the port, flushing may introduce the core into the patient’s body, and could lead to serious adverse events.
      • When possible, upon accessing the port, consider aspirating a small amount of blood from the port after septum puncture, then discard the syringe with its contents. This step may recapture the silicone sliver. If the needle becomes clogged when attempting to aspirate, remove the needle, discard it and select a new one.
      • Watch for signs and/or symptoms that may indicate damage to the port’s septum, such as medication leakage resulting in inadequate therapy delivery, along with tissue, nerve and/or muscle damage; and redness of the surrounding area.
      • Patients should continue to follow their doctor’s recommendations for receiving treatment.
    Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death.
    Health care professionals and consumers may report adverse reactions or quality problems they experienced using these products to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by FAX.
    Useful Links:

    List of Affected Products: Navilyst Medical, Inc. Vaxcel Implantable Vascular Access Systems Containing Huber Needles: Products Affected by the Class I Huber Needle Recall. This list also includes those products labeled under Boston Scientific.
    NAVILYST MEDICAL INC. PRODUCTS
    ProductCatalog NumberUPN NumberLot Number
    Vaxcel Port with PASV Titanium Mini-Port with PASV Valve and 6F Polyurethane Catheter (1.1 mm/1.9 mm)
    Navilyst Medical Logo. Follow link for full printed address.
    45-213M001452130
    119232712525841303564
    119422812581011307354
    119810312590571307625
    119971712637101308513
    120069912668091313095
    120353312676891316267
    121435212713091343197
    121464812736981346939
    121565612765971354063
    121902212803291360019
    122562712851431364758
    122841112868321365528
    123246212903631369511
    123561712926681373470
    123903912940481377611
    124089812958634001730
    124426212976704006506
    124615512991664014211
    12510201300520
    Vaxcel Port with PASV Titanium Mini-Port With PASV Valve and 8F Polyurethane Catheter (1.6 mm/2.6 mm)
    Navilyst Medical Logo. Follow link for full printed address.
    45-215M001452150
    119395212423091316807
    119422912442631319163
    119457912455411323431
    119842112470371325747
    119971812484311330396
    120216712539401333308
    120353412570221336009
    120868212581021340118
    120989512595161343198
    121059412637111346938
    121435312643231347894
    121435412657701351419
    121464912676901354064
    121500012681341355339
    121684912726621359540
    121838812744101361868
    121902312764201364432
    121991412783391366291
    122017212815701368296
    122087112825821369512
    122594012851441371077
    122699912870971372172
    122841212886481372901
    122980012921581373965
    123045712940491374540
    123071612958641375756
    123246312981071377315
    123353213001174000285
    123531913041464001731
    123654713073554003056
    123904013092614006508
    123932013105034007735
    124003513134674014212


    4014213
    Vaxcel Port with PASV Titanium Mini-Port with PASV Valve and 8F Silicone Catheter (1.4 mm/2.6 mm)
    Navilyst Medical Logo.
    45-220M001452200
    119395312484321311034
    119531112505271313096
    119810412525851313097
    120070012570231348374
    120245712581031353274
    120461412637121355601
    120734012657711356197
    120766412676911365529
    121435512739011367037
    121465012776331368843
    121565712810301370103
    121685012851451372521
    122119112886491374541
    122700012940481377316
    122841312944801377612
    123114312958651377844
    123246412961411378093
    123532012967091378345
    123904112979231380085
    123932113005211381887
    124089913073564000284
    124426413073574001732
    124703813073584007724


    4014661
    Vaxcel Port Titanium Mini-Port with 6F Polyurethane Catheter (1.1 mm/1.9 mm)
    Navilyst Medical Logo.
    45-303M001453030
    12676921320987
    12832421327651
    12845661344772
    12900251359287
    12964101366292
    13005241370777
    13069631377613
    13125904001733
    Vaxcel Port Titanium Mini-Port with 7F Polyurethane Catheter (1.3 mm/2.2 mm)
    Navilyst Medical Logo.
    45-305M001453050
    12637131302380
    12676931309262
    12832431310743
    12876051319164
    12928651323675
    12998601357022

    1372173
    Vaxcel Port Titanium Mini-Port with 8F Silicone Catheter (1.5 mm/2.6 mm)
    Navilyst Medical Logo.
    45-310M001453100
    126371412860801321707
    126477512870981345647
    126769412886501346950
    126971412926691354323
    127232012944811355340
    127369912950721359541
    127550212976711360401
    127659812995941364170
    128324413012921367275
    128410013100321373685
    128514613123221381270
    128540013168084001734
    Vaxcel Port Titanium Standard Port with 9F Polyurethane Catheter (1.8 mm/2.8 mm)
    Navilyst Medical Logo.
    45-315M001453150
    12643241294761
    12774621304148
    12883051320497

    1356811


    Vaxcel Port Titanium Standard Port with 8F Silicone Catheter (1.5 mm/2.6 mm)
    Navilyst Medical Logo.
    45-320M0014532001264960 1283246 1342235 1371638
    Vaxcel Port Plastic Standard Port with 8F Silicone Catheter (1.5 mm/2.6 mm)
    Navilyst Medical Logo.
    45-340M0014534001263715 1277463 1294482 1332871
    Vaxcel Port Plastic Standard Port with 9F Polyurethane Catheter (1.8 mm/2.8 mm)
    Navilyst Medical Logo.
    45-360M0014536001267697 1290638 1317254 1342462 1362918
    Vaxel Port with PASV Titanium Standard Port with PASV Valve and 8F Polyurethane Catheter (1.6 mm/2.6 mm)
    Navilyst Medical Logo.
    45-362M001453620
    119233212525861341521
    119810612570281349623
    120217212581071351954
    120495612621111357024
    120689512655361359288
    120868412676981362390
    121435912681351363949
    121465112752161365530
    121966612783431371855
    122790412863591373199
    123005612886511374542
    123114412928661377845
    123399312958661379701
    123966513059784001736
    124325313083084007727
    124554513149934010947
    124843613212141282267D
    12512341329618
    Vaxcel Port with PASV Titanium Standard Port with PASV Valve and 8F Silicone Catheter (1.4 mm/2.6 mm)
    Navilyst Medical Logo.
    45-364M001453640
    119395712432541296998
    119810712501351299862
    119842312525871307903
    119945412570291311285
    120070112584241316268
    120636212668101334583
    121436012676991351212
    122433312773081354065
    122841812783441355341
    122980312851471365531
    123904412855941367038
    124003712894761370574


    4007741
    Vaxcel Port w PASV Plastic Standard Port with PASV Valve and 8F Polyurethane Catheter (1.6 mm/2.6 mm)
    Navilyst Medical Logo.
    45-366M001453660
    119395812501361327177
    119810812570301332149
    120495712607601336928
    121436112637161341264
    121685112677001344773
    122341312718961347895
    122563112783451353759
    122763112787991356587
    122841912817541359289
    122980412851481362391
    123114512903641363950
    123287012940501366735
    123399412974261372174
    123532113059791373686
    123904513073591376248
    123966613087671380992
    124325513116904001737
    124704013182144010940


    4014270
    Vaxcel Port with PASV Plastic Standard Port with PASV Valve and 8F Silicone Catheter (1.4 mm/2.6 mm)
    Navilyst Medical Logo.
    45-368M001453680
    119233412442651285401
    119273912484371290026
    119810912525881290639
    120103112570311292159
    121465212581081294051
    121685212610211294762
    121966712655371295867
    122980512659951296142
    123287112677011302934
    123561812701351305980
    123904612755031307360
    123932312765991334584
    124426512776341364172
    123904612815714000283
    12393231285149
    BOSTON SCIENTIFIC PRODUCTS
    ProductCatalog NumberUPN NumberLot Number
    Vaxcel Port with PASV Titanium Mini-Port with PASV Valve and 6F Polyurethane Catheter (1.1 mm/1.9 mm)
    Boston Scientific Logo. Follow link for full address.
    45-213M001452130
    119232712324621267689
    119422812356171271309
    119810312390391273698
    119971712408981276597
    120069912442621280329
    120353312461551285143
    121435212510201286832
    121464812525841290363
    121565612581011292668
    121902212590571294048
    122562712637101295863
    122841112668091297670
    Vaxcel Port with PASV Titanium Mini-Port With PASV Valve and 8F Polyurethane Catheter (1.6 mm/2.6 mm)
    Boston Scientific Logo. Follow link for full address.
    45-215M001452150
    119395212199141244263
    119422912201721245541
    119457912208711247037
    119842112259401248431
    119971812269991253940
    120216712284121257022
    120353412298001259516
    120868212304571263711
    120989512307161264323
    121059412324631265770
    121435312335321267690
    121435412353191268134
    121464912365471288648
    121500012390401292158
    121684912393201295864
    121838812400351300117
    12190231242309
    Vaxcel Port with PASV Titanium Mini-Port with PASV Valve and 8F Silicone Catheter (1.4 mm/2.6 mm)
    Boston Scientific Logo.
    45-220M001452200
    119395312270001258103
    119531112284131265771
    119810412311431267691
    120070012324641273901
    120245712353201277633
    120461412390411281030
    120734012393211285145
    120766412408991288649
    121435512442641294480
    121465012470381295865
    121565712484321296141
    121685012505271296709
    122119112525851297923
    Vaxcel Port Titanium Mini-Port with 6F Polyurethane Catheter (1.1 mm/1.9 mm)
    Boston Scientific Logo. Follow link for full address.
    45-303M0014530301284566
    Vaxcel Port Titanium Mini-Port with 8F Silicone Catheter (1.5 mm/2.6 mm)
    Boston Scientific Logo. Follow link for full address.
    45-310M0014531001273699 1285400 1286080 1287098
    Vaxcel Port Titanium Standard Port with 9F Polyurethane Catheter (1.8 mm/2.8 mm)
    Boston Scientific Logo. Follow link for full address.
    45-315M0014531501294761
    Vaxel Port with PASV Titanium Standard Port with PASV Valve and 8F Polyurethane Catheter (1.6 mm/2.6 mm)
    Boston Scientific Logo. Follow link for full address.
    45-362M001453620
    119233212279041252586
    119810612300561267698
    120217212311441268135
    120495612339931278343
    120689512396651286359
    120868412432531295866
    121435912455451305978
    121465112484361282267D
    12196661251234
    Vaxcel Port with PASV Titanium Standard Port with PASV Valve and 8F Silicone Catheter (1.4 mm/2.6 mm)
    Boston Scientific Logo. Follow link for full address.
    45-364M001453640
    119395712432541267699
    119810712501351277308
    119842312525871285147
    119945412570291296998
    12007011258424
    Vaxcel Port w PASV Plastic Standard Port with PASV Valve and 8F Polyurethane Catheter (1.6 mm/2.6 mm)
    Boston Scientific Logo. Follow link for full address.
    45-366M001453660
    119395812311451260760
    119810812328701263716
    120495712339941267700
    121436112353211278345
    121685112390451278799
    122341312396661281754
    122563112432551285148
    122763112470401290364
    122841912501361294050
    122980412570301297426
    Vaxcel Port with PASV Plastic Standard Port with PASV Valve and 8F Silicone Catheter (1.4 mm/2.6 mm)
    Boston Scientific Logo. Follow link for full address.
    45-368M001453680
    119233412442651281571
    119273912390461285149
    119810912393231285401
    120103112442651290026
    121465212484371290639
    121685212525881292159
    121966712610211294051
    122980512655371294762
    123287112677011295867
    123561812701351296142
    123904612765991302934
    123932312776341305980

    Addresses

    Navilyst Medical
    Legal Manufacturer
    Navilyst Medical, Inc.
    26 Forest Street
    Marlborough, MA 01752 USA
    USA customer Service 800 833-9973
    Made in the USA
    10 Glens Falls Technical Park
    Glens Falls, NY 12801 USA
    Boston Scientific
    Medi-Tech®

    Boston Scientific Corporation
    One Boston Scientific Place
    Natick, MA 01760-1537
    USA
    USA Customer Service 888 272-1001

    LinkWithin

    Related Posts Widget for Blogs by LinkWithin